Karyopharm Therapeutics Inc. (KPTI)
Develops cancer drugs that block a protein helping tumor cells survive and spread.
$7.09+0.00%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+80.4%
The outlook
KPTI trades at $7.09, sitting well below its 50- and 200-day moving averages after a weak price trend. Analyst consensus is strongly bullish with an average price target around $14.80, roughly double the current price. The stock sits in the lower half of its 52-week range, reflecting recent underperformance despite positive sentiment from coverage.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 5 analysts
Price trendBelow its 50- & 200-day averages
52-week range47% of the way from its 52-week low to high
Price targetAvg target +109% vs current price
Analyst price target
~12-month · 5 analysts$14.80average target+108.7% vs now
Now $7.09
Low $13.00High $16.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$160.7M
52-wk high
$10.99
52-wk low
$3.65
50-day avg
$8.96
200-day avg
$7.64
Trailing P/E
—